Evidence map›Paper›PMID 34090648›Full record

ReviewSeminars in radiation oncology2021

Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease.

Duygu Sezen, Vivek Verma, Kewen He, Chike O Abana, Hampartsaum Barsoumian, Matthew S Ning, Chad Tang, Pervin Hurmuz, Nahum Puebla-Osorio, Dawei Chen and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Seminars in radiation oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Duygu SezenDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Radiation Oncology, Koc University School of Medicine, Istanbul, Turkey.
Vivek VermaDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Kewen HeDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong, People's Republic of China.
Chike O AbanaDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Hampartsaum BarsoumianDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Matthew S NingDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Chad TangDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Pervin HurmuzDepartment of Radiation Oncology, Hacettepe University School of Medicine, Ankara, Turkey.
Nahum Puebla-OsorioDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Dawei ChenDepartment of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong, People's Republic of China.
Irwin TendlerDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Nathan ComeauxDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Quynh-Nhu NguyenDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Joe Y ChangDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
James W WelshDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: jwelsh@mdanderson.org.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Metastatic cancer is inherently heterogeneous, and patients with metastatic disease can experience vastly different oncologic outcomes depending on several patient- and disease-specific characteristics. Designing trials for such a diverse population is challenging yet necessary to improve treatment outcomes for metastatic-previously thought to be incurable-disease. Here we review core considerations for designing and conducting clinical trials involving radiation therapy and immunotherapy for patients with metastatic cancer.

Indexed as

ImmunotherapyNeoplasmsClinical Trials as TopicCombined Modality TherapyHumansRadiotherapy

Identifiers

PMID34090648
PMCPMC11907639

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.